Ulcerative colitis is a chronic inflammatory bowel disease that affects the lining of the colon and rectum. Medications help reduce inflammation, control symptoms, and maintain remission. Treatment options include aminosalicylates, corticosteroids, immunomodulators, biologics, and targeted oral therapies. Each medication class works differently and may cause specific side effects. Understanding these treatments, their potential risks,
Ulcerative colitis can cause symptoms such as diarrhea, abdominal pain, rectal bleeding, and an urgent need to pass stools. Treatment depends on disease severity, the area of the colon affected, previous treatment responses, and individual health circumstances. Some medications help control active inflammation, while others are used to maintain remission and reduce the risk of future flare-ups. Understanding medication benefits and potential side effects is an important part of ongoing disease management.
Several medication classes are used to treat ulcerative colitis. Healthcare professionals select treatments according to symptoms, disease activity, medical history, and treatment goals.
Aminosalicylates: Medicines such as mesalamine and sulfasalazine reduce inflammation in the intestinal lining. They are commonly used for mild to moderate ulcerative colitis. Possible side effects include nausea, headache, abdominal discomfort, and diarrhea. Rarely, kidney problems or other serious reactions can occur.
Corticosteroids: Prednisone and budesonide may be prescribed to control moderate or severe inflammation during a flare. Side effects can include increased appetite, weight gain, mood changes, elevated blood sugar, and difficulty sleeping. Long-term systemic corticosteroid use can increase the risk of osteoporosis, infections, and adrenal suppression. These medicines are generally not intended for long-term maintenance of remission.
Immunomodulators: Azathioprine and mercaptopurine suppress certain immune responses and may help maintain remission in selected patients. Potential side effects include nausea, reduced blood cell counts, liver problems, and an increased risk of infections. Regular blood tests are important during treatment.
Biologic therapies: Medicines such as infliximab, adalimumab, vedolizumab, and ustekinumab target specific immune pathways involved in inflammation. Possible side effects include injection-site reactions, infusion reactions, and infections. Screening for certain infections may be required before treatment.
Targeted oral medications provide additional treatment options for some adults with moderate to severe ulcerative colitis. These therapies act on particular pathways involved in the immune response. Their suitability depends on disease severity, previous treatments, and individual risk factors.
Patients should discuss existing medical conditions, other medicines, vaccination status, and monitoring requirements with their healthcare professionals before starting a new treatment.
Janus kinase inhibitors: Tofacitinib and upadacitinib are oral medicines that affect immune signaling. Potential side effects include infections, acne, headache, and changes in cholesterol levels. Certain patients may face increased risks of serious infections, blood clots, major cardiovascular events, or some cancers.
Sphingosine 1 phosphate receptor modulators: Ozanimod and etrasimod affect immune cell movement. Possible side effects include headache, elevated liver enzymes, and changes in heart rate. Eye problems and infections may also require consideration.
Monitoring and follow-up: Depending on the medication, monitoring may include blood counts, liver and kidney function, infection screening, or other assessments. Patients should report new or worsening symptoms and avoid changing or stopping prescribed treatment without medical guidance.
Recognizing serious reactions: Severe abdominal pain, persistent heavy rectal bleeding, high fever, difficulty breathing, or signs of a serious infection require prompt medical assessment. Severe or rapidly worsening symptoms may require emergency care.
Medication selection for ulcerative colitis involves balancing symptom control, remission goals, treatment effectiveness, and possible adverse effects. Regular follow-up helps healthcare professionals assess whether treatment is working and whether adjustments are needed. Patients can support informed treatment decisions by keeping track of symptoms, taking medicines as directed, and discussing concerns about side effects with their healthcare team.